Corvia Medical
Corvia Medical is dedicated to revolutionizing the treatment of heart failure through innovative transcatheter cardiovascular devices, including the Corvia Atrial Shunt System and the InterAtrial Shunt Device (IASD®). The company focuses on providing minimally invasive solutions to reduce elevated left atrial pressure, improve quality of life, and decrease hospitalizations in heart failure patients, especially those with preserved or mid-range ejection fraction. Backed by prominent investors and with a history of clinical trials and regulatory milestones, Corvia aims to transform heart failure care and bring its therapies to patients worldwide.
Industries
Nr. of Employees
small (1-50)
Corvia Medical
One Highwood Drive, Suite 300, Tewksbury, MA 01876, USA
Patents
Apparatus and methods to create and maintain an intra-atrial pressure relief opening
US-12303119-B2
View DetailsApparatus and methods to create and maintain an intra-atrial pressure relief opening
US-11589854-B2
View Details
Apparatus and methods to create and maintain an intra-atrial pressure relief opening
US-12303119-B2
View DetailsApparatus and methods to create and maintain an intra-atrial pressure relief opening
US-11589854-B2
View DetailsProducts
Interatrial shunt implant (catheter-deployed)
A minimally invasive, catheter-delivered intracardiac implant designed to create a controlled passage between the left and right atria to lower left atrial pressure and relieve symptoms in patients with preserved or mildly reduced ejection fraction.
Interatrial shunt implant (catheter-deployed)
A minimally invasive, catheter-delivered intracardiac implant designed to create a controlled passage between the left and right atria to lower left atrial pressure and relieve symptoms in patients with preserved or mildly reduced ejection fraction.
Services
Sponsorship, design and operational management of global multicenter clinical trials, including randomized, double-blind, sham-controlled studies and continued-access protocols.
Clinical training and education programs for interventional cardiologists and electrophysiologists on implantation technique, patient selection and procedural best practices.
Online platform and support to identify clinical trial centers and treatment centers offering the implant therapy.
Preparation and management of regulatory submissions and continued-access protocols to maintain patient access while pre-market review is ongoing.
Sponsorship, design and operational management of global multicenter clinical trials, including randomized, double-blind, sham-controlled studies and continued-access protocols.
Clinical training and education programs for interventional cardiologists and electrophysiologists on implantation technique, patient selection and procedural best practices.
Online platform and support to identify clinical trial centers and treatment centers offering the implant therapy.
Preparation and management of regulatory submissions and continued-access protocols to maintain patient access while pre-market review is ongoing.
Expertise Areas
- Clinical trial management (multicenter randomized, double-blind, sham-controlled)
- Interventional cardiology device development
- Structural heart implant engineering
- Regulatory affairs for implantable medical devices (FDA, EU MDR)
Key Technologies
- Transcatheter interatrial shunt implant (catheter-deployed)
- Catheter-based cardiac implant delivery systems
- Minimally invasive transcatheter procedural techniques
- Exercise hemodynamic assessment
News & Updates
Achieved CE certification under EU MDR 2017/745, enabling marketing in Europe.
First patients randomized in the global trial evaluating the IASD for heart failure with preserved or mid-range ejection fraction.
The trial evaluates the efficacy of the IASD in reducing elevated left atrial pressure in HFpEF and HFmrEF patients.
Two-year data from the REDUCE LAP-HF II trial shows durable safety and efficacy, with significant reductions in heart failure events and improvements in quality of life.
Three-year follow-up data demonstrates a 44% reduction in heart failure events and a 46% improvement in quality of life in responder patients.
Echocardiographic data shows positive effects on heart structure and function over two years.
Achieved CE certification under EU MDR 2017/745, enabling marketing in Europe.
First patients randomized in the global trial evaluating the IASD for heart failure with preserved or mid-range ejection fraction.
The trial evaluates the efficacy of the IASD in reducing elevated left atrial pressure in HFpEF and HFmrEF patients.
Two-year data from the REDUCE LAP-HF II trial shows durable safety and efficacy, with significant reductions in heart failure events and improvements in quality of life.
Three-year follow-up data demonstrates a 44% reduction in heart failure events and a 46% improvement in quality of life in responder patients.
Echocardiographic data shows positive effects on heart structure and function over two years.